Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.
Biologic drugs
Psoriasis Area and Severity Index (PASI)
long-term therapy
real-world
secukinumab
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
17
5
2023
pubmed:
8
4
2023
entrez:
7
4
2023
Statut:
ppublish
Résumé
Long-term real-life data on secukinumab use in psoriasis are limited. Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life. Multicenter retrospective study analyzing data from adult patients treated with secukinumab for at least 192 weeks and up to 240 weeks in Southern Italy, between 2016 and 2021. Clinical data, including concurrent comorbidities and prior treatments were collected. Effectiveness was assessed by Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) scores at the initiation of secukinumab and at weeks 4, 12, 24, 48, 96, 144, 192, and 240. Two hundred and seventy-five patients (174 males), mean age 50.80 ± 14.78 years, were included; 29.8% had an uncommon localization, 24.4% psoriatic arthritis, 71.6% comorbidities. PASI, BSA, and DLQI improved significantly from week 4 and continued to improve over time. Between weeks 24 and 240, PASI score was mild (≤10) in 97-100% of patients, 83-93% had mild affected BSA (BSA ≤ 3), and 62-90% reported no effect of psoriasis on their quality of life (DLQI 0-1). Only 2.6% of patients reported adverse events and no patient discontinued the treatment during the study period. Secukinumab effectiveness in the long-term treatment of psoriasis is confirmed in real-world.
Sections du résumé
BACKGROUND
UNASSIGNED
Long-term real-life data on secukinumab use in psoriasis are limited.
OBJECTIVES
UNASSIGNED
Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life.
METHODS
UNASSIGNED
Multicenter retrospective study analyzing data from adult patients treated with secukinumab for at least 192 weeks and up to 240 weeks in Southern Italy, between 2016 and 2021. Clinical data, including concurrent comorbidities and prior treatments were collected. Effectiveness was assessed by Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) scores at the initiation of secukinumab and at weeks 4, 12, 24, 48, 96, 144, 192, and 240.
RESULTS
UNASSIGNED
Two hundred and seventy-five patients (174 males), mean age 50.80 ± 14.78 years, were included; 29.8% had an uncommon localization, 24.4% psoriatic arthritis, 71.6% comorbidities. PASI, BSA, and DLQI improved significantly from week 4 and continued to improve over time. Between weeks 24 and 240, PASI score was mild (≤10) in 97-100% of patients, 83-93% had mild affected BSA (BSA ≤ 3), and 62-90% reported no effect of psoriasis on their quality of life (DLQI 0-1). Only 2.6% of patients reported adverse events and no patient discontinued the treatment during the study period.
CONCLUSIONS
UNASSIGNED
Secukinumab effectiveness in the long-term treatment of psoriasis is confirmed in real-world.
Identifiants
pubmed: 37026590
doi: 10.1080/09546634.2023.2200868
doi:
Substances chimiques
secukinumab
DLG4EML025
Antibodies, Monoclonal
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM